Home LiteratureArticle Details
PMID: 9738982 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.

Japanese journal of cancer research : Gann ·Vol. 89 ·No. 7 ·1998-07-00 ·Pages 748-56

Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y

Abstract

Treatment with IDEC-C2B8 (C2B8), the chimeric anti-CD20 antibody, was shown in a phase I-II study to be very effective for the treatment of low-grade B-cell lymphoma, in contrast to the results of most previous immunotherapies with monoclonal antibodies. In a study designed to elucidate the reason for this efficacy, two cell lines derived from lymphomas with BCL2 gene rearrangement (SU-DHL-4 and SU-DHL-6) showed remarkable growth inhibition and cell-death, and two other cell lines derived from a diffuse lymphoma (RC-K8) and a mantle cell lymphoma (SP-49) showed moderate growth inhibition, but neither a CD20 weakly positive cell line (NALL-1) nor a negative cell line (MOLT-4) showed any growth inhibition. An examination of the intensity of cell-surface CD20 expression showed no correlation between intensity and degree of growth inhibition among the four cell lines showing growth inhibition. Morphological examination revealed condensed and fragmented nuclei and budding of the plasma membrane, both characteristic of apoptosis, with some cells in these cell lines showing growth inhibition by C2B8. Such apoptosis was also confirmed by flow cytometric analysis, suggesting that, at least in part, apoptosis plays a role in this growth inhibition. This growth-inhibitory mechanism may thus account for the effectiveness of C2B8 antibody therapy.

MeSH Terms
Animals Antibodies, Monoclonal/therapeutic use Antigens, CD20/analysis,immunology Apoptosis Cell Division Humans Lymphoma, B-Cell/pathology,therapy Mice Recombinant Fusion Proteins/therapeutic use Tumor Cells, Cultured
Chemicals
Antibodies, Monoclonal Antigens, CD20 Recombinant Fusion Proteins
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Taji H
Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Nagoya.
Kagami Y
Okada Y
Andou M
Nishi Y
Saito H
Seto M
Morishima Y
References (30)
30 references, click to expand
  1. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
    Blood. 1994 Oct 15;84(8):2457-66 PMID: 7522629
  2. Monoclonal antibody-based therapies of leukemia and lymphoma.
    Blood. 1992 Aug 15;80(4):863-78 PMID: 1498329
  3. Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations.
    Cancer Res. 1991 Dec 15;51(24):6708-11 PMID: 1742746
  4. Engagement of CD20 suppresses apoptosis in germinal center B cells.
    Eur J Immunol. 1995 Nov;25(11):3160-4 PMID: 7489758
  5. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
    Blood. 1994 Jan 15;83(2):435-45 PMID: 7506951
  6. Human leukemic "null" cell line (NALL-1).
    Cancer. 1977 Nov;40(5):2131-5 PMID: 200333
  7. Quantitative analysis of leukocyte membrane antigen expression: normal adult values.
    Cytometry. 1996 Jun 15;26(2):137-47 PMID: 8817090
  8. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    N Engl J Med. 1992 Oct 22;327(17):1209-15 PMID: 1406793
  9. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.
    Br J Cancer. 1972 Aug;26(4):239-57 PMID: 4561027
  10. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
    J Immunol. 1984 Aug;133(2):1028-36 PMID: 6376628
  11. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
    Blood. 1989 May 1;73(6):1431-9 PMID: 2713487
  12. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
    Lancet. 1988 Dec 17;2(8625):1394-9 PMID: 2904526
  13. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.
    J Immunol. 1985 Dec;135(6):3795-801 PMID: 2415587
  14. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.
    Blood. 1994 Sep 1;84(5):1415-20 PMID: 8068938
  15. Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy adult donors.
    Cytometry. 1996 Dec 15;26(4):265-74 PMID: 8979025
  16. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes.
    Eur J Immunol. 1986 Aug;16(8):881-7 PMID: 3091375
  17. Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia.
    Biochem Biophys Res Commun. 1973 Apr 2;51(3):529-35 PMID: 4512981
  18. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis).
    Cytometry. 1997 Jan 1;27(1):1-20 PMID: 9000580
  19. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
    J Immunol. 1985 Aug;135(2):973-9 PMID: 3925015
  20. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
    Blood. 1997 May 1;89(9):3129-35 PMID: 9129015
  21. Establishment of a new human B cell line carrying t(11;14) chromosome abnormality.
    Jpn J Cancer Res. 1987 Nov;78(11):1182-5 PMID: 3121553
  22. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro.
    Blood. 1995 Jan 15;85(2):532-40 PMID: 7812008
  23. Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40.
    Eur J Immunol. 1992 Dec;22(12):3141-8 PMID: 1280225
  24. CD20: a regulator of cell-cycle progression of B lymphocytes.
    Immunol Today. 1994 Sep;15(9):450-4 PMID: 7524522
  25. Immunoglobulin gene rearrangements and expression in diffuse histiocytic lymphomas reveal cellular lineage, molecular defects, and sites of chromosomal translocation.
    Blood. 1986 Feb;67(2):391-7 PMID: 3080039
  26. A clinical trial of anti-idiotype therapy for B cell malignancy.
    Blood. 1985 Jun;65(6):1349-63 PMID: 3888313
  27. Monoclonal antibodies in diagnosis and therapy.
    Science. 1991 Jun 21;252(5013):1657-62 PMID: 2047874
  28. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.
    Cell. 1985 Jul;41(3):899-906 PMID: 3924412
  29. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
    Blood. 1998 Mar 1;91(5):1644-52 PMID: 9473230
  30. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.
    J Exp Med. 1989 May 1;169(5):1747-56 PMID: 2469768
Article Info
Journal
Japanese journal of cancer research : Gann
Abbr.
Jpn J Cancer Res
ISSN
0910-5050
DOI
10.1111/j.1349-7006.1998.tb03280.x
Published
1998-07-00
Pages
748-56
Language
English
Region
Japan
NLM ID
8509412
PMCID
PMC5921892
Subset
IM
External Links
PubMed source DOI: 10.1111/j.1349-7006.1998.tb03280.x PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2